Get the Stockscreener App
2.90
0.34%
-0.01
After Hours:
2.91
0.01
+0.34%
Esperion Therapeutics Inc stock is traded at $2.90, with a volume of 6.40M.
It is down -0.34% in the last 24 hours and down -15.20% over the past month.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
See More
Previous Close:
$2.91
Open:
$2.95
24h Volume:
6.40M
Relative Volume:
1.34
Market Cap:
$694.48M
Revenue:
$116.33M
Net Income/Loss:
$-209.25M
P/E Ratio:
-1.3679
EPS:
-2.12
Net Cash Flow:
$-135.49M
1W Performance:
-12.91%
1M Performance:
-15.20%
6M Performance:
+14.62%
1Y Performance:
+63.84%
1-Day Range:
$2.75
$3.02
1-Week Range:
$2.75
$3.385
52-Week Range:
$0.6925
$4.175
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.905 | 695.67M | 116.33M | -209.25M | -135.49M | -2.12 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.98 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.48 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.88 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Piper Sandler | Overweight |
| Dec-18-24 | Initiated | Goldman | Neutral |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-20-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-01-23 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Jun-15-23 | Upgrade | BofA Securities | Underperform → Buy |
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
electroCore, Inc. (ECOR) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Finviz
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - TradingView
Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements - Yahoo Finance UK
Esperion to acquire Corstasis for cardiovascular franchise expansion - Pharmaceutical Technology
Esperion Therapeutics: $75 Million Acquisition Of Corstasis To Expand Cardiovascular Franchise With Enbumyst Nasal Spray - Pulse 2.0
Deal Watch: Esperion Augments Cardiovascular Franchise Via Corstasis Buyout - Citeline News & Insights
Esperion Therapeutics (NASDAQ:ESPR) Shares Down 13.1%Should You Sell? - MarketBeat
Ann Arbor pharmaceutical company to pay $75M in deal for new drug - Crain's Detroit Business
Esperion Therapeutics (NASDAQ:ESPR) Given New $5.00 Price Target at Needham & Company LLC - MarketBeat
Esperion to acquire Corstasis Therapeutics - The Pharma Letter
Esperion Acquires Enbumyst Maker Corstasis - Bitget
Esperion Acquires Enbumyst Maker Corstasis - Benzinga
Esperion to Acquire Corstasis, Expanding Heart Failure Portfolio - TipRanks
Esperion Therapeutics to Acquire Corstasis for $75 Million Upfront, Plus Up to $180 Million Milestones - TradingView
Esperion (NASDAQ: ESPR) adds Enbumyst CHF drug in Corstasis acquisition - Stock Titan
Esperion Therapeutics to Acquire Corstasis for $75 Million in Cash - marketscreener.com
Esperion Therapeutics to acquire Corstasis Therapeutics, expands cardiovascular portfolio with Enbumyst nasal spray - Traders Union
Esperion to acquire Enbumyst maker for $75M plus milestones - Investing.com
ESPR: Acquisition brings a novel FDA-approved nasal spray diuretic, expanding cardiovascular offerings - TradingView
Esperion Therapeutics and Corstasis Therapeutics Announce - GlobeNewswire
ESPR Should I Buy - Intellectia AI
ESPR SEC FilingsEsperion Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Esperion Therapeutics Inc devrait afficher une perte de 13 cents par actionEarnings AVANT-PAPIER - TradingView
Esperion Therapeutics (ESPR) Earnings Expected to Grow: Should You Buy? - Finviz
Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10 - The Manila Times
Cholesterol drug biopharma Esperion sets March 10 results webcast - Stock Titan
Esperion Therapeutics (ESPR) to Release Earnings on Tuesday - MarketBeat
How Esperion Therapeutics Inc. stock benefits from tech adoption2025 Biggest Moves & Technical Entry and Exit Tips - mfd.ru
Why is Esperion Therapeutics Inc. stock going upJuly 2025 EndofMonth & Free Community Consensus Stock Picks - mfd.ru
Aug Setups: Can Esperion Therapeutics Inc outperform under higher oil pricesQuarterly Risk Review & Capital Efficient Trading Techniques - baoquankhu1.vn
Esperion to Participate in The 2026 Citizens Life Sciences Conference - Bitget
Esperion settles another lawsuit to keep generic versions of popular drug off shelves - Cardiovascular Business
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL and NEXLIZET Prior to April 19, 2040 - marketscreener.com
How to listen to Esperion at the 2026 Citizens Life Sciences event - Stock Titan
Setup Watch: What is the next catalyst for Esperion Therapeutics IncWeekly Risk Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Esperion Therapeutics: Past The Turnaround, Waiting On Guidelines (NASDAQ:ESPR) - Seeking Alpha
Esperion Therapeutics (ESPR) has signed a settlement agreement with a fifth generic drug applicant. - Bitget
Esperion settles patent dispute with Alkem over cholesterol drugs - Investing.com
Esperion and Alkem Laboratories Settle Patent Litigation Over NEXLETOL and NEXLIZET - Quiver Quantitative
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) & NEXLIZET (bempedoic acid & ezetimibe) Prior to April 19, 2040 - Bitget
Esperion Reaches Settlement Agreement with Fifth ANDA Filer - GlobeNewswire
Aug Volume: Is Esperion Therapeutics Inc. still a buy after recent gains2025 Key Highlights & Free Community Consensus Stock Picks - mfd.ru
Gibson Energy Inc. (OTCMKTS:GBNXF) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
What’s the fair value of Esperion Therapeutics Inc. stockAnalyst Upgrade & Low Risk High Reward Ideas - mfd.ru
Esperion Therapeutics (NASDAQ:ESPR) Downgraded by Wall Street Zen to "Hold" - MarketBeat
What is the next catalyst for Esperion Therapeutics Inc.Stock Surge & Weekly Return Optimization Plans - mfd.ru
Is Esperion Therapeutics Inc. in a bullish channelJuly 2025 Price Swings & Weekly Chart Analysis and Trade Guides - mfd.ru
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm
Market Trends: How does Esperion Therapeutics Inc. score in quality rankings2025 Key Highlights & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
What is the next catalyst for Esperion Therapeutics IncWeekly Investment Report & Expert Curated Trade Setups - baoquankhu1.vn
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
0.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):